-
Study aim
-
Clinical evaluation of 3D-printed implants made of hydroxyapatite and polycaprolactone for the treatment of eye orbit lesions.
-
Design
-
It is a non-randomized single-group clinical trial with 500 patients receiving 3D-printed orbit implants enrolling between February 2024 and February 2027 and will be followed for 1 year.
-
Settings and conduct
-
A total of 500 patients will receive these implants. The surgical placement of the implants are carried out in a hospital setting under the supervision of a qualified surgeon, with subsequent closure of the skin. Post-surgery, the patient undergoes clinical assessment within 7 to 10 days. At the 6-month mark, a follow-up appointment is scheduled for evaluation of the orbital region, including vision correction if necessary. Based on the doctor's assessment, CT scan images will be taken one-year post-surgery to assess bone regeneration and the integrity of the implants.
-
Participants/Inclusion and exclusion criteria
-
Patients who suffer from bone defects in the orbital region of the eye are eligible for the study. Patients with a history of undergoing cancer therapy, diabetes, osteoporosis, tobacco use, challenges with anesthesia administration, and susceptibility to antibiotics are excluded from participating in this research.
-
Intervention groups
-
The intervention group is to investigate the effectiveness of 3D-printed biodegradable implants made of polycaprolactone and hydroxyapatite (40% wt), which are placed in patients with bone injuries of the eye orbit due to accidents, osteotomy, or congenital reasons. Implants are placed in the lesion during surgery and after anesthesia, and the skin is sutured after the procedure. These implants are made in collaboration with Adli Tissue Regeneration.
-
Main outcome variables
-
Newly formed bone density; the rate of new bone formation; biodegradation rate of the implant; symmetry matching of eyes and orbit region